Orlando, FL – February 4, 2025 – TruTechnologies, a leader in clinical trial oversight, is proud to announce the launch of TruScreen, a groundbreaking solution debuting at the SCOPE Summit in Orlando, Florida, on February 4, 2025. Designed to tackle one of the most persistent challenges in clinical trials, TruScreen helps reduce screen failures, eliminate wasted site efforts, and accelerate the enrollment of qualified patients.

Addressing the Root Causes of Enrollment Inefficiencies
Clinical trial sponsors invest significant time and resources in activating sites, yet many struggle with zero enrollers—sites that complete startup but fail to screen or enroll a single patient. TruScreen provides sponsors with real-time visibility into site activity, ensuring proactive intervention before valuable time and budget are wasted. With TruScreen, sponsors can:

• Identify at-risk sites early and determine whether to provide additional support or shift resources.
• Encourage sites to proactively recruit patients and keep studies at the forefront of investigators' minds.
• Capture data on patient eligibility trends, helping sponsors understand site-level screening patterns and refine recruitment strategies accordingly.
• Improve site relations by facilitating more meaningful sponsor-site engagement throughout recruitment.

Solving the Patient Screening Bottleneck
Patient enrollment is not just about finding patients—it’s about finding qualified patients within strict protocol timelines. From the moment a patient consents, sites face a short and hectic window to complete screening. TruScreen helps:

• Monitor site-level screening efficiency in real-time, identifying where delays occur.
• Provide accountability for pre-screening efforts, ensuring sites remain actively engaged.
• Analyze the root causes of screen failures, such as protocol complexity, I/E criteria misalignment, or patient non-interest.
• Reduce the burden of rescreening, ensuring more patients are successfully enrolled the first time.

Synergy with TruLab
When used together, TruScreen and TruLab provide sponsors with a comprehensive view of both patient eligibility and sample tracking, ensuring protocol adherence at every stage. Screening samples often play a critical role in determining eligibility, and TruScreen integrates seamlessly with TruLab to maintain consistency between patient screening data and biospecimen management. Additionally, all data on each patient is consolidated from pre-screening through study participation, allowing for a more connected and informed decision-making process.

‍About TruTechnologies
Founded in 2018, TruTechnologies is the leading provider of real-time clinical trial oversight, focused on enabling timely, high-quality data and mitigating risks in drug development. The company partners with six top 20 pharmaceutical companies and numerous biotechnology firms to accelerate patient screening and enrollment, drive protocol adherence, and correct deviations.

Media Contact:
Sarah Sinning
Marketing Associate
sarah.sinning@tru.team
+1 (919) 972-8475